BUDGET IMPACT ANALYSIS OF REGORAFENIB FOR THE TREATMENT IN THIRD AND FOURTH LINES OF METASTASIC COLORECTAL CANCER IN SPAIN
Author(s)
González Flores E1, Vera García R2, Sabater Cabrera E3, Tirado Mercier E4, Granell Villalon M5
1Hospital Universitario Virgen de las Nieves, Granada, Spain, 2Complejo Hospitalario de Navarra, Pamplona, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 4Bayer Hispania S. L., Sant Joan Despí (Barcelona), Spain, 5Bayer Hispania S. L., Sant Joan Despí ( Barcelona ), Spain
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCN64
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now